Extended Data Fig. 8: Intratumour heterogeneity of DLBCL1 sample.
a–c) ScRNA profiles of malignant B cells from the DLBCL1 sample only (3114 cells) were subjected to t-SNE and coloured by CD48 (a), SELL (b) and MYC (c) expression. d) DLBCL1 derived lymph node cells were stained for viability, CD19, CD3, CD48, CD62L and MYC or respective isotype control. Histograms show fluorescence intensity of MYC for isotype control, T cells, CD48HighCD62L+ and CD48LowCD62L− subpopulations. Experiment was repeated three times with similar results. E-G) DLBCL1 derived lymph node cells were incubated with DMSO, I-BET-762 (e) at two concentrations (1 µM, 5 µM), OTX015 (f) at two concentrations (1 µM, 5 µM), or ibrutinib (g) at two concentrations (0.2 µM, 1 µM). After 24 hours, cells were harvested and stained as described in panel d. Histograms show fluorescence intensity for CD48HighCD62L+ subclone. Experiment was repeated three times with similar results. H) Line plot shows total cluster-specific copy number estimation of DLBCL1 sample for all chromosomes as indicated using whole genome sequencing. DMSO: Dimethyl sulfoxide. See Source Data Extended Data Fig. 8.
